News | May 04, 2009

FDA Grants HUD Designation for Pericardium Covered Stents for Perforations, Dissections of Coronaries, Vein Grafts

The Aneugraft pericardium covered stent designed to treat perforations and dissections or coronary arteries.

May 5, 2009 - ITGI Medical Ltd. Said last week the FDA granted HUD (humanitarian use device) designation to Over and Under and Aneugraft pericardium covered stents for treatment of perforations and dissections of native coronary arteries and saphenous vein grafts.

HUD is the first step towards obtaining market approval from the FDA, the company said.

The Over and Under and AneuGraft are stents that are covered 100 percent with a heterologous tissue designed as a barrier between the coronary blood vessel wall and its lumen. Stents are commercially available in Europe, Israel and Latin America for treatment of saphenous vein graft stenosis, aneurysms and for emergency situations such as perforations.

Pericardium covered stents are unique stents covered with heterologous tissue designed to set a barrier between the blood vessel wall and its lumen. Pericardium covered stents are indicated for treatment of bypass stenosis, aneurysms and for emergency situations such as perforations.

ITGI medical is engaged in research and development, manufacturing and marketing of heterologous tissue covered stents.

For more information: www.itgimedical.com

Related Content

Gore Announces First-in-Human Use of Gore TAG Conformable Thoracic Stent Graft
News | Stent Grafts| July 17, 2017
W. L. Gore & Associates Inc. announced the first patient implant of the Gore TAG Conformable Thoracic Stent Graft...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair
News | Endovascular Aortic Repair| May 23, 2017
Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and...
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
News | Stent Grafts| April 06, 2017
Endologix Inc. announced that the first patients were treated in the Expanding Patient Applicability with Polymer...
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Overlay Init